TSE:VMD
10.87
0.05
(0.46%)
Viemed Healthcare
VMD-T
Analysis and Opinions about VMD-T
Signal
Opinion
Expert
DON'T BUY
DON'T BUY
He didn't like it for a while, but now more than before. The telehealth space is getting crowded and they've had issues with CMS code. It's a good American company, though doesn't receive much attention here. VMS is merely okay. He prefers other names like Knight Therapeutics. It's a decent, second-tier company.
HOLD
HOLD
October 6, 2020
He got stopped out of it a while ago. VMD relies on Medicare for a lot of revenues. Clients use sleep-aid systems that are put through Medicare. This revenue stream is coming up for review by Medicare , so this is a risk. Otherwise, VMD checks a lot of boxes. Hold.
Show full opinionHide full opinion
He got stopped out of it a while ago. VMD relies on Medicare for a lot of revenues. Clients use sleep-aid systems that are put through Medicare. This revenue stream is coming up for review by Medicare , so this is a risk. Otherwise, VMD checks a lot of boxes. Hold.
BUY
BUY
June 30, 2020
They provide home equipment and therapy to deal with sleep apnea and other respiratory issues. Earnings are expected to grow 75%. 2021 ROE 37% as earnings rocket up, expected to jump 85% in 2020 and 16% in 2021. PE is 18x 2020, and 22x in 2021. Positive free cash flow which should double. It could join a U.S. index which will boost the stock. $15.25 price target or 9% upside.
Show full opinionHide full opinionThey provide home equipment and therapy to deal with sleep apnea and other respiratory issues. Earnings are expected to grow 75%. 2021 ROE 37% as earnings rocket up, expected to jump 85% in 2020 and 16% in 2021. PE is 18x 2020, and 22x in 2021. Positive free cash flow which should double. It could join a U.S. index which will boost the stock. $15.25 price target or 9% upside.
TOP PICK
TOP PICK
April 27, 2020
They provide non-invasive ventilators. Medicare is no longer going through a competitive bidding process. (Analysts’ price target is $13.07)
Show full opinionHide full opinionThey provide non-invasive ventilators. Medicare is no longer going through a competitive bidding process. (Analysts’ price target is $13.07)
COMMENT
COMMENT
October 7, 2019
It broke above $3.20 and so far it looks okay, but this trades at low volumes.
Show full opinionHide full opinionIt broke above $3.20 and so far it looks okay, but this trades at low volumes.
PAST TOP PICK
PAST TOP PICK
September 23, 2019
(A Top Pick Sep 24/18, Up 44%) He got stopped out, a mistake. Very profitable, no debt. But they had concentration risk--they need to diversify their customer base. He might buy them back.
Show full opinionHide full opinion(A Top Pick Sep 24/18, Up 44%) He got stopped out, a mistake. Very profitable, no debt. But they had concentration risk--they need to diversify their customer base. He might buy them back.
TOP PICK
TOP PICK
May 29, 2019
They are in the non-evasive respiratory product market for COPD. Their recent earnings showed 45% increase in revenues. Trades at 20 times earnings, but he thinks they can continue to grow into that. Yield 0%. (Analysts’ price target is $12.50)
Show full opinionHide full opinionThey are in the non-evasive respiratory product market for COPD. Their recent earnings showed 45% increase in revenues. Trades at 20 times earnings, but he thinks they can continue to grow into that. Yield 0%. (Analysts’ price target is $12.50)
WAIT
WAIT
May 17, 2019
They make breathing masks for sleep apnea patients. Earnings are forecast to $0.35 per share growing to $0.60 next year. A reasonable multiple then.
Show full opinionHide full opinionThey make breathing masks for sleep apnea patients. Earnings are forecast to $0.35 per share growing to $0.60 next year. A reasonable multiple then.
BUY
BUY
May 1, 2019
Have enjoyed 25% margins. They faced speculation of increasing competition, which pressured the stock, so VMD replied that that competition lies years ahead and won't affect them. This trades at a decent 12x next year's earnings. Once VMD lists in the US, their stock price will jump up.
Show full opinionHide full opinionHave enjoyed 25% margins. They faced speculation of increasing competition, which pressured the stock, so VMD replied that that competition lies years ahead and won't affect them. This trades at a decent 12x next year's earnings. Once VMD lists in the US, their stock price will jump up.
WEAK BUY
WEAK BUY
April 17, 2019
Small company. Market cap around $250 mill. Not very followed. Decent growth on the revenue side of around 40%. Still have to spend that money. The regulatory issues are big. Very competitive space. But they are very good at it.
Show full opinionHide full opinionSmall company. Market cap around $250 mill. Not very followed. Decent growth on the revenue side of around 40%. Still have to spend that money. The regulatory issues are big. Very competitive space. But they are very good at it.
STRONG BUY
STRONG BUY
April 4, 2019
He almost made it a Top Pick this time. It is a great company and he continues to love it. They were a former sleep management company and are now in the sleep apnea and oxygen space. He adds when the stock sells off. Over time it will continue to higher until it gets taken out.
Show full opinionHide full opinionHe almost made it a Top Pick this time. It is a great company and he continues to love it. They were a former sleep management company and are now in the sleep apnea and oxygen space. He adds when the stock sells off. Over time it will continue to higher until it gets taken out.
COMMENT
COMMENT
January 21, 2019
Took a beating from $8 to $4 upon news about a regulatory change that effected their medical products. He sold his shares. They rely on medicaid and Medicare, but he'd rather see them diversify their revenue base (which they're talking about doing). Good managers, though; he's met them. VMD was too volatile for him. If you own this and can stomach this volatility, VMD will eventually supply a good return.
Show full opinionHide full opinionTook a beating from $8 to $4 upon news about a regulatory change that effected their medical products. He sold his shares. They rely on medicaid and Medicare, but he'd rather see them diversify their revenue base (which they're talking about doing). Good managers, though; he's met them. VMD was too volatile for him. If you own this and can stomach this volatility, VMD will eventually supply a good return.
BUY
BUY
October 4, 2018
They are an interesting company, spun out of the PHM-X group. They have been executing very well. There was a study that looked at what happens when people are closely monitored and it was very in favour in terms of what Biomed does. This is home monitoring of the COPD disease so they can push them out of hospitals sooner. They were growing at 20% per year organically. He continues to own it. PHM-X also looks really attractive now.
They are an interesting company, spun out of the PHM-X group. They have been executing very well. There was a study that looked at what happens when people are closely monitored and it was very in favour in terms of what Biomed does. This is home monitoring of the COPD disease so they can push them out of hospitals sooner. They were growing at 20% per year organically. He continues to own it. PHM-X also looks really attractive now.
TOP PICK
TOP PICK
September 24, 2018
They're the number three player in U.S. respiratory providers. They were spun out of Patient Home Monitoring. 30% ROE. As long as they execute and grow organically, their stock price will rise in 1-2 years. (no dividend, Anaylsts' price target: $9.75)
They're the number three player in U.S. respiratory providers. They were spun out of Patient Home Monitoring. 30% ROE. As long as they execute and grow organically, their stock price will rise in 1-2 years. (no dividend, Anaylsts' price target: $9.75)
BUY
BUY
July 24, 2018
Provides breathing masks and other respiratory support services. He expects significant growth and sees it as reasonably priced relative to projected earnings.
Provides breathing masks and other respiratory support services. He expects significant growth and sees it as reasonably priced relative to projected earnings.
Showing 1 to 15
of 15 entries
- «
- ‹
- 1
- ›
- »
Viemed Healthcare(VMD-T) Rating
Ranking : 3 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 1
Bearish - Sell Signals / Votes : 1
Total Signals / Votes : 3
Viemed Healthcare(VMD-T) Frequently Asked Questions
What is Viemed Healthcare stock symbol?
Viemed Healthcare is a Canadian stock, trading under the symbol VMD-T on the Toronto Stock Exchange (VMD-CT). It is usually referred to as TSX:VMD or VMD-T
Is Viemed Healthcare a buy or a sell?
In the last year, 3 stock analysts published opinions about VMD-T. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for Viemed Healthcare.
Is Viemed Healthcare a good investment or a top pick?
Viemed Healthcare was recommended as a Top Pick by Peter Hodson on 2020-11-17. Read the latest stock experts ratings for Viemed Healthcare.
Why is Viemed Healthcare stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Viemed Healthcare worth watching?
3 stock analysts on Stockchase covered Viemed Healthcare In the last year. It is a trending stock that is worth watching.
What is Viemed Healthcare stock price?
On 2021-01-21, Viemed Healthcare (VMD-T) stock closed at a price of $10.87.
He didn't like it for a while, but now more than before. The telehealth space is getting crowded and they've had issues with CMS code. It's a good American company, though doesn't receive much attention here. VMS is merely okay. He prefers other names like Knight Therapeutics. It's a decent, second-tier company.